Peter Attia· MD
so now what you explained was because they have difficulties getting a patent for this compound they created this reduced version of methylene blue and it's similar studies but in that study they had the problem that the majority of the people if you are having Alzheimer's disease and you're in a hospital or being treated by usually a neurologist or sometimes like a dress they would prescribe unfortunately unfortunately drugs that have no benefit through the patients but use verse effects such as calling histories inhibitors and memantine and the idea being is well this is the standard of care it would be quote unquote unethical to take these patients off these agents even to allow them to enter another trial well that may be the reasoning that some people may have but that's actually the opposite or what's happening these drugs are ineffective and he's unethical to continue to use these ineffective dolls that are having this toxic and birth effects on people